Neratinib + Loperamide + Colestipol + Budesonide
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Stage HER2+ Breast Cancer
Conditions
Early Stage HER2+ Breast Cancer
Trial Timeline
Feb 1, 2015 → Apr 22, 2021
NCT ID
NCT02400476About Neratinib + Loperamide + Colestipol + Budesonide
Neratinib + Loperamide + Colestipol + Budesonide is a phase 2 stage product being developed by Puma Biotechnology for Early Stage HER2+ Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02400476. Target conditions include Early Stage HER2+ Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02400476 | Phase 2 | Completed |
Competing Products
20 competing products in Early Stage HER2+ Breast Cancer